U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H31NO6
Molecular Weight 429.506
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SARPOGRELATE

SMILES

COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1

InChI

InChIKey=FFYNAVGJSYHHFO-UHFFFAOYSA-N
InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)

HIDE SMILES / InChI

Molecular Formula C24H31NO6
Molecular Weight 429.506
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/sarpogrelate.html | https://www.ncbi.nlm.nih.gov/pubmed/10980267 | https://clinicaltrials.gov/ct2/show/NCT01165567 | http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF

Sarpogrelate (brand name Anplag; former developmental code names MCI-9042, LS-187,118) is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. It blocks serotonin-induced platelet aggregation and has applications in the treatment of many diseases including diabetes mellitus, Buerger's disease, Raynaud's disease, coronary artery disease, angina pectoris, and atherosclerosis.

CNS Activity

Curator's Comment: According to information supplied by the manufacturers, the brain tissue concentration of sarpogrelate was 0.25–0.5% of the plasma concentration, in a w14 tracer experiment using Cx-labeled sarpogrelate

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.38 nM [Ki]
6.11 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Anplag

Approved Use

INDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion
Preventing
Anplag

Approved Use

INDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion
PubMed

PubMed

TitleDatePubMed
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
2001 Jul
Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists.
2001 Nov
Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart.
2001 Sep
Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries.
2002 Feb 1
[Pharmacological analysis of inhibitory effect of sarpogrelate hydrochloride on human radial artery contraction].
2002 Jan
Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.
2002 Nov
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs].
2003
Efficacy of serotonin receptor blocker for symptomatic lumbar disc herniation.
2003 Jun
Sarpogrelate treatment reduces restenosis after coronary stenting.
2003 Mar
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
2003 May
The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.
2003 May
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
2003 May 30
Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts.
2004 Dec
Electroencephalographical effects of sarpogrelate hydrochloride versus ticlopidine hydrochloride in elderly patients with peripheral atherosclerosis.
2004 May-Jun
Functions of 5-HT2A receptor and its antagonists in the cardiovascular system.
2004 Oct
Therapeutic potentials of sarpogrelate in cardiovascular disease.
2004 Spring
Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?
2005
New treatment of lumbar disc herniation involving 5-hydroxytryptamine2A receptor inhibitor: a randomized controlled trial.
2005 Apr
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
2005 Sep
Impaired potency of bone marrow mononuclear cells for inducing therapeutic angiogenesis in obese diabetic rats.
2006 Apr
Site-directed mutagenesis of the serotonin 5-Hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding.
2006 Aug
Homology modelling of the serotoninergic 5-HT2c receptor.
2006 Jun
Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.
2006 May
Livedo racemosa as a cutaneous manifestation of polycythemia vera.
2006 May-Jun
Identification of amino acid residues important for sarpogrelate binding to the human 5-hydroxytryptamine2A serotonin receptor.
2006 Sep
Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia.
2006 Sep
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury.
2006 Sep 27
Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
2007
Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate.
2007
Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, attenuates neurogenic pain induced by nucleus pulposus in rats.
2007 Feb 1
Identification of a key amino acid of the human 5-HT(2B) serotonin receptor important for sarpogrelate binding.
2007 Jul
Synthesis and 5-HT2A, 5-HT1A and alpha1-binding affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) benzyl oximes.
2007 Mar
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
2008 Apr
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.
2008 Fall
The effects of a 5-HT2A receptor antagonist on blood flow in lumbar disc herniation: application of nucleus pulposus in a canine model.
2008 Feb
Serotonin induces vasoconstriction of smooth muscle cell-rich neointima through 5-hydroxytryptamine2A receptor in rabbit femoral arteries.
2008 Jul
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial.
2008 Jun
Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.
2008 Sep-Oct
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.
2009
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
2009 Aug
Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats.
2009 Jul 1
Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.
2010 Jan
Patents

Patents

Sample Use Guides

The usual dosage for adult patients is 100 mg of sarpogrelate hydrochloride, administered after meal three times a day. The dosage may be adjusted according to the patient’s age and symptoms.
Route of Administration: Oral
Stably expressing cell lines were constructed in HEK293 cells by transfecting with Lipofectamine 2000 reagent and selecting with 0.5 mg/ml G418-containing growth medium. Cells were split into 24-well plates at a density of 105 cells /well and labeled with 3 μCi/ml [3H]myo-inositol in serum-free DMEM for 24 h. Then the cells were washed with the assay medium (20 mM LiCl, 130 mM NaCl, 900 μM NaH2PO4, 5.4 mM KCl, 1.8 mM CaCl2, and 25 mM glucose in 20 mM HEPES, pH 7.4) and incubated with both SARPOGRELATE (10−9 – 10−4 M) at 37°C for 1 h. Cell extracts, in 10 mM formic acid, were applied to a 1-ml AG1-X8 resin (100 – 200 mesh; Assist Co., Tokyo) column before elution by buffer containing 1 M ammonium formate and 0.1 M formic acid. Radioactivity was measured by a liquid scintillation spectrophotometer.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:29:31 UTC 2023
Edited
by admin
on Wed Jul 05 23:29:31 UTC 2023
Record UNII
19P708E787
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SARPOGRELATE
INN   WHO-DD  
INN  
Official Name English
Sarpogrelate [WHO-DD]
Common Name English
BUTANEDIOIC ACID, 1-(2-(DIMETHYLAMINO)-1-((2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)METHYL)ETHYL) ESTER
Systematic Name English
4-(1-(2-(3-METHOXYPHENETHYL)PHENOXY)-3-(DIMETHYLAMINO)PROPAN-2-YLOXY)-4-OXOBUTANOIC ACID SARPOGRELATE
Common Name English
BUTANEDIOIC ACID, MONO(2-(DIMETHYLAMINO)-1-((2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)METHYL)ETHYL) ESTER
Common Name English
sarpogrelate [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1327
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
NCI_THESAURUS C66885
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID7048328
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
INN
6611
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
CAS
135309-80-7
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
SUPERSEDED
PUBCHEM
5160
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
EVMPD
SUB10455MIG
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
FDA UNII
19P708E787
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
DRUG CENTRAL
2423
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
MESH
C064294
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
DRUG BANK
DB12163
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
NCI_THESAURUS
C73158
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
ChEMBL
CHEMBL52939
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
SMS_ID
100000084098
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
IUPHAR
210
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
CAS
125926-17-2
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
WIKIPEDIA
SARPOGRELATE
Created by admin on Wed Jul 05 23:29:31 UTC 2023 , Edited by admin on Wed Jul 05 23:29:31 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY